openPR Logo
Press release

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pharmaceutical Pipeline Review, H2 2017

09-01-2017 09:49 AM CET | Health & Medicine

Press release from: Market Research Hub - Pharmaceutical Industry

Market_Research_Hub

Market_Research_Hub

Market Research Hub (MRH) added a new research report to its vast database titled “Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) Pipeline Review, H2 2017” targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development with respective active and dormant or discontinued projects.

Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1313666

Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 1 and 2 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Gastrointestinal which include indications Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma, Breast Cancer, Colon Cancer, Colorectal Cancer, Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Malignant Mesothelioma, Medullary Thyroid Cancer, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Lung Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Pancreatic Cancer, Peritoneal Tumor and Recurrent Glioblastoma Multiforme (GBM).

The latest report Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 - Pipeline Review, H2 2017, outlays comprehensive information on the Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope:
- The report provides a snapshot of the global therapeutic landscape for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)
- The report reviews Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics

Browse Full Report with TOC @ http://www.marketresearchhub.com/report/carcinoembryonic-antigen-related-cell-adhesion-molecule-5-carcinoembryonic-antigen-or-cea-or-meconium-antigen-100-or-cd66e-or-ceacam5-pipeline-review-h2-2017-report.html

Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Content:

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Overview
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

….continue

Make an Enquiry @ http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1313666

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients and customers.

Contact Us
90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)

Email: press@marketresearchhub.com

Website: http://www.marketresearchhub.com/

Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pharmaceutical Pipeline Review, H2 2017 here

News-ID: 694513 • Views:

More Releases from Market Research Hub - Pharmaceutical Industry

Global Enthesopathy Treatment Market Analysis by Type, Application, Top Key Players are-Abbott Laboratories, Eli Lilly, Janssen Biotech, Pfizer, Siemens and Forecast 2019-2025
Global Enthesopathy Treatment Market Analysis by Type, Application, Top Key Play …
The global market status for Enthesopathy Treatment is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Global Enthesopathy Treatment Market Size, Status and Forecast 2019-2025”, which tends to deliver in-depth knowledge associated to the Enthesopathy Treatment market for the present and forecasted period until 2025. Furthermore, the report examines the target market based on market size,
Global BioImaging Technologies Market Status, Growth Opportunity, Scope, Key Players:-Hologic, Hitachi, Digirad, FONAR, Covidien, Mindray and Forecast 2019-2025
Global BioImaging Technologies Market Status, Growth Opportunity, Scope, Key Pla …
The market for BioImaging Technologies is growing with the expansion of this Industry Sector Worldwide. Market Research Hub (MRH) has added a new report titled “Global BioImaging Technologies Market Size, Status and Forecast 2019-2025” which offer details about the current trends and analysis, as well as scope for the near future. This research study also covers information about the production, consumption and market share based on different active regions. Furthermore,
Global Drugs and Diagnostics for Hematological Disorders Market Report Overview 2019-2025 | Top Players are-Abbot, Pfizer, Mindray, Roche, Biorad, Siemens
Global Drugs and Diagnostics for Hematological Disorders Market Report Overview …
Market Research Hub (MRH) has actively included a new research study titled “Global Drugs and Diagnostics for Hematological Disorders Market Size, Status and Forecast 2019-2025” to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period
Global Biosimilar Testing and Development Services Market Report Overview 2019-2025 | Top Players are-Eurofins Scientific, Exova, Source BioScience, Intertek Group, Sigma-Aldrich
Global Biosimilar Testing and Development Services Market Report Overview 2019-2 …
Market Research Hub (MRH) has actively included a new research study titled “Global Biosimilar Testing and Development Services Market Size, Status and Forecast 2019-2025” to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until

All 5 Releases


More Releases for Antigen

New HGH Saliva Antigen Covid Test gamechanger
An Austrian company HGH Disinfection und Cosmetique Gmbh, based in 9020 Klagenfurt created with a Korean partner a unique antigen salvia test unit which is so simple that anybody can use it. Till now mass testing was nasal stick by government and doctors. Now this new test unit can be used by everybody without a scarry stick in the nose and a result with 95% is ready in 10
p53 Antigen Modulators Therapeutics- Pipeline Analysis 2018 |
p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage. p53 antigen modulators helps in preventing cancer development through regulation of cell cycle and apoptosis. Download the sample report @ https://www.pharmaproff.com/request-sample/1195 Thus, new opportunities in cancer immunotherapy are expected to develop better drug candidates targeting p53, with complete understanding of interactions between p53 and the immune system, to avoid various
Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Anti …
ReportsWorldwide has announced the addition of a new report title Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also
CancerTestis Antigen 1 (Autoimmunogenic CancerTestis Antigen NY ESO 1 or CancerT …
ReportsWorldwide has announced the addition of a new report title CancerTestis Antigen 1 (Autoimmunogenic CancerTestis Antigen NY ESO 1 or CancerTestis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) -
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cance …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Pipeline Review, H2 2017”. Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Cancer/Testis
B-Cell Maturation Antigen Targeted Therapies Market
Multiple myeloma is an incurable disease of plasma cells, which needs some intervention by clinical researchers. However, there have been recent success in developing such therapy that can be effective in hematologic malignancies such as chimeric antigen receptor CAR-T cell therapy, which is expected to be promising in cancer treatment. However, researchers have found little success in finding a specific target antigen under CAR T-cell therapies for treating multiple myeloma.